Clinical efficacy of magnesium sulfate injection in the treatment of masseter muscle trigger points: a randomized clinical study

Shaimaa Mohsen Refahee, Aliaa Ibrahim Mahrous, Alshaimaa Ahmed Shabaan, Shaimaa Mohsen Refahee, Aliaa Ibrahim Mahrous, Alshaimaa Ahmed Shabaan

Abstract

Objective: Myofascial pain syndrome with trigger points is the most common cause of nonodontogenic pain. Although injection of the trigger points is the most effective pain reduction treatment, many patients exhibit recurrence after a short period. Therefore, the aim of the current study was to evaluate the clinical efficacy of magnesium sulfate injections in the treatment of the masseter muscle trigger points when compared to saline injections.

Material and method: This study randomly (1:1) assigned 180 patients to one of two treatment groups based on whether their trigger points were injected with 2 ml of saline or magnesium sulfate. Pain scores, maximum mouth opening (MMO), and quality of life were measured at the pre-injection and 1, 3, and 6 months post-injection.

Results: The pain scores were significantly higher in the saline group during all follow-up assessments, whereas the MMO was significantly higher in the magnesium sulfate group up to 3 months of follow-up (p < 0.001). However, the difference in MMO ceased to be statistically significant after 6 months of follow-up (p = 0.121). Additionally, the patient's quality of life score was significantly higher in the magnesium sulfate group compared to the saline group (p < 0.001).

Conclusion: Injection of magnesium sulfate is an effective treatment measure for myofascial trigger points. However, further studies with a proper design addressing the limitations of the current study are necessary.

Clinicaltrials: org (ID: NCT04742140) 5/2/2021.

Keywords: Injection; Magnesium sulfate; Masseter muscle; Myofascial trigger point; Saline.

Conflict of interest statement

The authors have no competing interests to declare.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Consort statement flow chart

References

    1. De Leeuw R, Klasser GD. Orofacial pain: guidelines for assessment, diagnosis, and managemen. Hanover Park Quintessence: Publishing, Incorporated, The American Academy of Orofacial Pain IL; 2018.
    1. Okeson JP. Orofacial pain: guidelines for assessment, diagnosis, and management. Chicago: Quintessence; 1996. p. 113–84.
    1. Okeson JP, de Leeuw R. Differential diagnosis of temporomandibular disorders and other orofacial pain disorders. Dent Clin North Am. 2011;55(1):105–120. doi: 10.1016/j.cden.2010.08.007.
    1. Bakke M, Möller E. Craniomandibular disorders and masticatory muscle function. Scand J Dent Res. 1992;100(1):32–38. doi: 10.1111/j.1600-0722.1992.tb01806.x.
    1. Frost HM. A 2003 update of bone physiology and Wolff's Law for clinicians. Angle Orthod. 2004;74(1):3–15. doi: 10.1043/0003-3219.
    1. Hong C. Myofascial pain therapy. J Musculoskelet Pain. 2004;12(3):37–43. doi: 10.1300/J094v12n03_06.
    1. Yilmaz O, Sivrikaya EC, Taskesen F, Pirpir C, Ciftci S. Comparison of the efficacy of botulinum toxin, local anesthesia, and platelet-rich plasma injections in patients with myofascial trigger points in the masseter muscle. J Oral Maxillofac Surg. 2021;79(1):88.e1–9. doi: 10.1016/j.joms.2020.09.013.
    1. Wong CSM, Wong SHS. A new look at trigger point injections. Anesthesiol Res Pract. 2012;2012:1–5. doi: 10.1155/2012/492452.
    1. Ibrahim NA, Raoof NA, Mosaad DM. Effect of magnesium sulfate iontophoresis on myofascial trigger points in the upper fibres of the trapezius. J Taibah Univ Medical Sci. 2021;16(3):369–378. doi: 10.1016/j.jtumed.2020.12.015.
    1. Dahle LO, Berg G, Hammar M, Hurtig M, Larsson L. The effect of oral magnesium substitution on pregnancy-induced leg cramps. Am J Obstet Gynecol. 1995;73(1):175–180. doi: 10.1016/0002-9378(95)90186-8.
    1. Albrecht E, Kirkham KR, Liu SS, Brull R. Peri-operative intravenous administration of magnesium sulphate and postoperative pain: a meta-analysis. Anaesthesia. 2013;68(1):79–90. doi: 10.1111/j.1365-2044.2012.07335.x.
    1. Yousef AA, Al-deeb AE. A double-blinded randomized controlled study of the value of sequential intravenous and oral magnesium therapy in patients with chronic low back pain with a neuropathic component. Anaesthesia. 2013;68(3):260–266. doi: 10.1111/anae.12107.
    1. Ghimirey KB, Ita K. Microneedle-assisted percutaneous transport of magnesium sulfate. Curr Drug Deliv. 2020;17(2):140–147. doi: 10.2174/1567201817666191217093936.
    1. General Assembly of the World Medical Association World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. J Am Coll Dent. 2014;81:14–18.
    1. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med. 2010;154(4):291–292. doi: 10.7326/0003-4819-154-4-201102150-00017.
    1. Sakalys D, Rokicki JP, Januzis G, Kubilius R. Plasma rich in growth factors injection effectiveness for myofascial pain treatment in masticatory muscles. Randomized controlled trial. J Oral Rehabil. 2020;47:796–801. doi: 10.1111/joor.12973.
    1. Reiter S, Goldsmith C, Emodi-Perlman A, Friedman-Rubin P, Winocur E. Masticatory muscle disorders diagnostic criteria: the American Academy of Orofacial Pain versus the research diagnostic criteria/temporomandibular disorders (RDC/TMD) J Oral Rehabil. 2012;39(12):941–947. doi: 10.1111/j.1365-2842.2012.02337.x.
    1. Nitecka-Buchta A, Walczynska-Dragon K, Batko-Kapustecka J, Wieckiewicz M. Comparison between collagen and lidocaine intramuscular injections in terms of their efficiency in decreasing myofascial pain within masseter muscles: a randomized, single-blind controlled trial. Pain Res Manag. 2018;2018:1–10.
    1. Taşkesen F, Cezairli B. The effectiveness of the masseteric nerve block compared with trigger point injections and dry needling in myofascial pain. CRANIO®. 2020; 16:1–6.
    1. Slade GD, Spencer AJ. Development and evaluation of the oral health impact profile. Commun Dent Health. 1994;11(1):3–11.
    1. Team RC: A Language and Environment for Statistical Computing (ed. Computing RFfS). Vienna, Austria. 2013.
    1. Venancio Rde A, Alencar FG, Jr, Zamperini C. Botulinum toxin, lidocaine, and dry-needling injections in patients with myofascial pain and headaches. Cranio. 2009;27(1):46–53. doi: 10.1179/crn.2009.008.
    1. Okada-Ogawa A, Sekine N, Watanabe K, Kohashi R, Asano S, Iwata K, Imamura Y. Change in muscle hardness after trigger point injection and physiotherapy for myofascial pain syndrome. J Oral Sci. 2019;61(1):36–44. doi: 10.2334/josnusd.17-0453.
    1. Kurtoglu C, Gur OH, Kurkcu M, Sertdemir Y, Guler-Uysal F, Uysal H. Effect of botulinum toxi- A in myofascial pain patients with or without functional disc displacement. J Oral Maxillofac Surg. 2008;66(8):1644–1651. doi: 10.1016/j.joms.2008.03.008.
    1. Romero-Reyes M. Uyanik JM Orofacial pain management: current perspectives. J Pain Res. 2014;7:99–115. doi: 10.2147/JPR.S37593.
    1. Fernandez-Carnero J, La Touche R, Ortega-Santiago R, Galan-del-Rio F, Pesquera J, Ge HY, Fernandez-de-Las-Penas C. Short-term effects of dry needling of active myofascial trigger points in the masseter muscle in patients with temporomandibular disorders. J Orofac Pain. 2010;24(1):106–112.
    1. Fiorillo L. Spine and TMJ: a pathophysiology report. J Funct Morphol Kinesiol. 2020;5(2):24. doi: 10.3390/jfmk5020024.
    1. Kamanli A, Kaya A, Ardicoglu O, Ozgocmen S, Zengin FO, Bayik Y. Comparison of lidocaine injection, botulinum toxin injection, and dry needling to trigger points in myofascial pain syndrome. Rheumatol Int. 2005;25(8):604–611. doi: 10.1007/s00296-004-0485-6.
    1. Nitecka-Buchta A, Walczynska-Dragon K, Kempa WM, Baron S. Platelet-rich plasma intramuscular injections - antinociceptive therapy in myofascial pain within masseter muscles in temporomandibular disorders patients: a pilot study. Front Neurol. 2019;10:250. doi: 10.3389/fneur.2019.00250.
    1. Classification GRD. epidemiology, and natural history of myofascial pain syndrome. Curr Pain Headache Rep. 2001;5(5):412–420. doi: 10.1007/s11916-001-0052-8.
    1. Alvarez DJ, Rockwell PG. Trigger points: diagnosis and management. Am Fam Phys. 2002;65(4):653–660.
    1. LeResche L. Epidemiology of temporomandibular disorders: implications for the investigation of etiologic factors. Crit Rev Oral Biol Med. 1997;8(3):291–305. doi: 10.1177/10454411970080030401.
    1. Nishio A, Gebrewold A, Altura BT, Altura BM. Comparative vasodilator effects of magnesium salts on rat mesenteric arterioles and venules. Arch Int Pharmacodyn Ther. 1989;298:139–163.
    1. Wang H, Liang QS, Cheng LR, Li XH, Fu W, Dai WT, Li ST. Magnesium sulfate enhances non-depolarizing muscle relaxant vecuronium action at adult muscle-type nicotinic acetylcholine receptor in vitro. Acta Pharmacol Sin. 2011;32(12):1454–1459. doi: 10.1038/aps.2011.117.
    1. Sane S, Mahdkhah A, Golabi P, Hesami SA, Kazemi HB. Comparison the effect of bupivacaine plus magnesium sulfate with ropivacaine plus magnesium sulfate infiltration on postoperative pain in patients undergoing lumbar laminectomy with general anesthesia. Br J Neurosurg. 2020;17:1–4. doi: 10.1080/02688697.2020.1861430.
    1. Ahmed SA, Magdy AA, Abdullah MA, Albadry AA. The effect of erector spinae plane block with and without addition of magnesium on relief of pain from post-herpetic neuralgia. Pain Phys. 2022;25(5):365–372.
    1. Fathy W, Hussein M, Ibrahim RE, Abdel-Aziz MM, Adel S, Soliman SH, Elmoutaz H, Abdelkader M. Comparative effect of transforaminal injection of Magnesium sulphate versus Ozone on oxidative stress biomarkers in lumbar disc related radicular pain. BMC Anesthesiol. 2022;22(1):254. doi: 10.1186/s12871-022-01789-0.
    1. Kirkland AE, Sarlo GL, Holton KF. The role of magnesium in neurological disorders. Nutrients. 2018;10(6):730. doi: 10.3390/nu10060730.
    1. Pouteau E, Kabir-Ahmadi M, Noah L, Mazur A, Dye L, Hellhammer J, Pickering G, DuBray C. Superiority of magnesium and vitamin B6 over magnesium alone on severe stress in healthy adults with low magnesemia: a randomized, single-blind clinical trial. PLoS ONE. 2018;13(12):1–17. doi: 10.1371/journal.pone.0208454.
    1. Schwalfenberg GK, Genuis SJ. The importance of magnesium in clinical healthcare. Scientifica. 2017;2017:4179326. doi: 10.1155/2017/4179326.
    1. Ng KT, Yap JLL, Izham IN, Teoh WY, Kwok PE, Koh WJ. The effect of intravenous magnesium on postoperative morphine consumption in noncardiac surgery: a systematic review and meta-analysis with trial sequential analysis. Eur J Anaesthesiol. 2020;37(3):212–223. doi: 10.1097/EJA.0000000000001164.
    1. Celiker R, Atalay A, Guven Z. Health-related quality of life in patients with myofascial pain syndrome. Curr Pain Headache Rep. 2010;14(5):361–366. doi: 10.1007/s11916-010-0141-7.
    1. Gazi MC, Issy AM, Avila IP, Sakata RK. Comparison of acupuncture to injection for myofascial trigger point pain. Pain Pract. 2011;11(2):132–138. doi: 10.1111/j.1533-2500.2010.00396.x.
    1. Brodsky M, Spritzer K, Hays RD, Hui KK. Change in health-related quality-of-life at group and individual levels over time in patients treated for chronic myofascial neck pain. J Evid Based Complement Altern Med. 2017;22(3):365–368. doi: 10.1177/2156587216662779.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit